These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33951425)

  • 41. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models.
    Wang X; Cottrell CA; Hu X; Ray R; Bottermann M; Villavicencio PM; Yan Y; Xie Z; Warner JE; Ellis-Pugh JR; Kalyuzhniy O; Liguori A; Willis JR; Menis S; Rämisch S; Eskandarzadeh S; Kubitz M; Tingle R; Phelps N; Groschel B; Himansu S; Carfi A; Kirsch KH; Weldon SR; Nair U; Schief WR; Batista FD
    Sci Immunol; 2024 May; 9(95):eadn0622. PubMed ID: 38753808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.
    Zhou T; Zhu J; Wu X; Moquin S; Zhang B; Acharya P; Georgiev IS; Altae-Tran HR; Chuang GY; Joyce MG; Kwon YD; Longo NS; Louder MK; Luongo T; McKee K; Schramm CA; Skinner J; Yang Y; Yang Z; Zhang Z; Zheng A; Bonsignori M; Haynes BF; Scheid JF; Nussenzweig MC; Simek M; Burton DR; Koff WC; ; Mullikin JC; Connors M; Shapiro L; Nabel GJ; Mascola JR; Kwong PD
    Immunity; 2013 Aug; 39(2):245-58. PubMed ID: 23911655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
    Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
    J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.
    Escolano A; Steichen JM; Dosenovic P; Kulp DW; Golijanin J; Sok D; Freund NT; Gitlin AD; Oliveira T; Araki T; Lowe S; Chen ST; Heinemann J; Yao KH; Georgeson E; Saye-Francisco KL; Gazumyan A; Adachi Y; Kubitz M; Burton DR; Schief WR; Nussenzweig MC
    Cell; 2016 Sep; 166(6):1445-1458.e12. PubMed ID: 27610569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.
    Cardozo T; Wang S; Jiang X; Kong XP; Hioe C; Krachmarov C
    Vaccine; 2014 Sep; 32(39):4916-24. PubMed ID: 25045827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
    Sliepen K; Sanders RW
    Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.
    de Taeye SW; Go EP; Sliepen K; de la Peña AT; Badal K; Medina-Ramírez M; Lee WH; Desaire H; Wilson IA; Moore JP; Ward AB; Sanders RW
    J Biol Chem; 2019 Apr; 294(14):5616-5631. PubMed ID: 30728245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.
    Pujanauski LM; Janoff EN; McCarter MD; Pelanda R; Torres RM
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1422-7. PubMed ID: 23288906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
    Gristick HB; von Boehmer L; West AP; Schamber M; Gazumyan A; Golijanin J; Seaman MS; Fätkenheuer G; Klein F; Nussenzweig MC; Bjorkman PJ
    Nat Struct Mol Biol; 2016 Oct; 23(10):906-915. PubMed ID: 27617431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts.
    Zhu J; Wu X; Zhang B; McKee K; O'Dell S; Soto C; Zhou T; Casazza JP; ; Mullikin JC; Kwong PD; Mascola JR; Shapiro L
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):E4088-97. PubMed ID: 24106303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
    Otsuka Y; Schmitt K; Quinlan BD; Gardner MR; Alfant B; Reich A; Farzan M; Choe H
    PLoS Pathog; 2018 Aug; 14(8):e1007238. PubMed ID: 30125330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization.
    Navis M; Tran K; Bale S; Phad GE; Guenaga J; Wilson R; Soldemo M; McKee K; Sundling C; Mascola J; Li Y; Wyatt RT; Karlsson Hedestam GB
    PLoS Pathog; 2014 Aug; 10(8):e1004337. PubMed ID: 25166308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice.
    Kosztyu P; Kuchar M; Cerny J; Barkocziova L; Maly M; Petrokova H; Czernekova L; Liskova V; Raskova Kafkova L; Knotigova P; Masek J; Turanek J; Maly P; Raska M
    EBioMedicine; 2019 Sep; 47():247-256. PubMed ID: 31544770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of a VRC01-like antibody lineage with immature V
    Hu Y; Li D; Yuan Z; Feng Y; Ren L; Hao Y; Wang S; Hu X; Liu Y; Hong K; Shao Y; Wang Z
    Mol Immunol; 2023 Feb; 154():11-23. PubMed ID: 36577292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
    Moore PL; Gorman J; Doria-Rose NA; Morris L
    Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development.
    Yuan T; Li J; Zhang Y; Wang Y; Streaker E; Dimitrov DS; Zhang MY
    Vaccine; 2011 Sep; 29(40):6903-10. PubMed ID: 21807049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
    Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
    Virology; 2017 May; 505():113-126. PubMed ID: 28237764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.